Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%

Longest survival data ever reported in a global Phase III trial in this setting

New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages